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Abstract
Objectives
Biologic agents have dramatically changed treatment of rheumatoid arthritis (RA). To date
only scarce head-to-head data exist especially when the biological therapies are given as
monotherapy without concomitant disease modifying drugs (DMARDs). Thus the objective
of the current study is to evaluate treatment response of all available biological therapies
with special focus on utility (EQ-5D-3L) and drug survival of biologic DMARDs (bDMARDs)
prescribed as monotherapy in RA patients in southern Sweden.
Materials and methods
All RA patients registered in a regional database as initiating bDMARD as monotherapy, i.e.
without concomitant conventional synthetic DMARDs (csDMARDs), from 1st of January
2006 through 31st of December 2012, were included. Patients were followed from initiation
of the first dose of bDMARD monotherapy treatment until withdrawal from treatment, loss of
follow-up or 31st of December 2012. Descriptive statistics for utility (EQ-5D-3L), effective-
ness, and drug survival of bDMARD monotherapy were calculated.
Results
During the study period, a total of 554 patients were registered in SSATG as initiating
bDMARD monotherapy. Most of the patients were women (81%), with a mean age of 57
years. The average disease duration was more than 12 years, and on average the patients
had previously been treated with approximately four different csDMARDs. Fifty-five percent
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of the patients were initiating their first bDMARD, 26% their second, and 19% their third or
more. At baseline the average EQ-5D-3L was 0.34. Most patients had moderate to high dis-
ease activity, with a mean DAS28 of 5.0, and were substantially disabled, with an average
HAQ score of 1.4. At 6 months´ follow-up, the EQ-5D-3L in patients still on the biologic drug
had increased by mean 0.23 (SD 0.4) with no differences between type of bDMARD (p =
0.49). The mean change in EQ-5D-3L ranged from 0.11 (rituximab and infliximab) to 0.42
(tocilizumab). Although the changes were numerically different, no distinct pattern favored
any particular bDMARD for EQ-5D-3L (p = 0.49) or other clinical outcomes. Overall, DAS28
defined remission and low disease activity were achieved in 20% and 43% of patients,
respectively. Drug survival rates were statistically significantly different between bDMARDs
(p = 0.01), with the highest rates observed for rituximab, followed by etanercept. After failing
first course of anti-TNF, patients switching to another mode of action had significantly higher
drug survival than those switching to a second course of anti-TNF therapy (p = 0.02).
Conclusions
Utility (EQ-5D-3L) increased after 6 months of all bDMARD treatments in monotherapy, indi-
cating improvement of patients’ quality of life. After failure of anti-TNF treatment in mono-
therapy, switching to another mode of action may be associated with better drug survival
than starting a second TNF-inhibitor.
Introduction
Rheumatoid arthritis (RA) patients should be treated as early as possible with disease-modify-
ing anti-rheumatic drugs (DMARDs) to improve the disease course [1]. Methotrexate (MTX)
is considered the anchor drug in RA, both on the basis of its efficacy and safety as monother-
apy, as well as its ability to increase the efficacy of biologic agents when used in combination
[2–5].
It is estimated that between 10 and 30% of RA patients are MTX-intolerant and discontinu-
ation is common in clinical practice [6]. Adverse effects from MTX include ulcerative stomati-
tis, leukopenia, liver toxicity, nausea and abdominal distress [7]. Thus, there are many reasons
for discontinuation of MTX during biologic DMARD (bDMARD) therapy or initiating at least
some of the bDMARDs as monotherapy. For those patients who are in need of treatment with
a bDMARD and cannot tolerate MTX, bDMARD monotherapy may be a good option. Effec-
tiveness and drug adherence of monotherapy with bDMARD has previously been described in
a cohort study of patients with RA registered in the Danish DANBIO registry [8].
It is well known that RA has significant socioeconomic impact defined as health loss associ-
ated with diseases including both morbidity and mortality [9]. The Global Burden of Disease
studies [10, 11] have recently addressed the challenges faced by the healthcare systems and, in
this context, the cost-effectiveness of treating RA is highly impacted by modern therapies [12].
Thus, it can be claimed that rheumatologists need to show responsibility and consider eco-
nomic implications when choosing between treatment options or modalities with comparable
efficacy and safety. With growing numbers of biosimilar bDMARDs in the field of rheumatol-
ogy, cost considerations by rheumatologists will become increasingly important [13]. In addi-
tion, stakeholders such as payers and administrators have to consider individual and societal
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implications (i.e. work disability and loss of productivity) of RA when making guidelines or
treatment recommendations regarding the use and implementation of bDMARDs.
However, little is known about utility gain in clinical practice. Moreover, reports from inde-
pendent cohorts in a similar clinical setting are lacking. The aim of this study was to investigate
the frequency and type of bDMARDs used in monotherapy in a representative sample of
patients with RA. Further, to evaluate and compare treatment response with special focus on
utility (EQ-5D) and tolerability (drug adherence) among the different bDMARDs. For this
purpose, we used the regional register held by the Southern Sweden Arthritis Treatment
Group (SSATG), which covers more than 90% of rheumatology patients treated with
bDMARDs [14] in southern Sweden setting, and can be considered representative of patients
with RA who are treated in routine care.
Materials and methods
Eligibility criteria, data summaries, and statistical analyses were based on a predefined proto-
col, which can be accessed through the first author. The outcomes were utility (EQ-5D-3L)
gain, disease activity score in 28 joints (DAS28) remission, DAS28 defined low disease activity
(LDA), the American College of Rheumatology response criteria 20%, 50%, 70% (ACR20,
ACR50, ACR70) after 6 months of follow-up, and drug adherence.
Study design, setting, and participants
RA patients who were registered in the SSATG database [14] as receiving initiation of treat-
ment with any bDMARD without concomitant conventional synthetic disease-modifying
anti-rheumatic drugs (csDMARD) therapy (i.e., monotherapy) in the period from 1st of Janu-
ary 2006 through 31st of December 2012 were included in the present study. There was no for-
mal definition of the initiation date of bDMARD monotherapy. The initiation date was based
on the decision of the treating physician, and most of the patients were exposed and intolerable
to csDMARDs prior to the bDMARD monotherapy initiation. A minority (about 3%) of the
patients had contra-indications for csDMARDs and was initiated directly on bDMARD
monotherapy. The patients were continuously enrolled and were monitored in the SSATG reg-
ister at baseline and during treatment. The patients were seen in the clinics at individual time
points. Patients were followed from initiation of the first dose of bDMARD monotherapy
treatment until withdrawal from treatment, loss of follow-up or 31st of December 2012. Drug
survival were retrieved from data recorded on withdrawals from treatment, which were rou-
tinely recorded by the treating physicians and classified as being due to adverse events, lack of
response/inefficacy, or miscellaneous reasons such as pregnancies, patient decisions, poor
compliance, and other unspecified causes. No formal criteria were required to terminate treat-
ment, and the decision was based on the judgment of the treating physician.
The study sample included RA patients on monotherapy from bio-initiation and through-
out the study period, whereas patients who became on monotherapy after cessation of con-
comitant csDMARD were excluded. A random sample of 50 patients from the SSATG
database was validated by TSJ with respect to monotherapy timelines for date of onset (first
dose bDMARD administered), dosage for the bDMARD monotherapy, and—in cases of with-
drawal—the date of first missing dose. The validation showed complete data recording except
for 1 patient (2%) with misrecorded termination date with monotherapy.
The regional ethics board of the University of Lund approved linkage of laboratory and
clinical data used for this study (No. 379/2011). Informed consent was not required for the
present study, as the study was part of a quality ensuring data recording process of routine
clinical care, where all data handling was anonymous.
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Variables
At the time of inclusion in the SSATG register, the following core data were recorded: diag-
nosis, year of disease onset, previous csDMARD treatment, and previous bDMARD treat-
ment. At treatment start (baseline) and at follow-up, utility gain (EQ-5D-3L based on British
tariff to improve external validity) was calculated [15, 16] on those still on the biologic drug
(EQ-5D-3L only exist on patients still on the drug). The EQ-5D is a five-dimensional health
state classification. The five dimensions are mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression. It is a preference-based measure that can be regarded as a con-
tinuous outcome scored on a -0.59 to 1.00 scale, with 1.00 indicating ‘full health’ and 0
representing dead [17]. The negative EQ-5D scores represent certain health states valued as
worse than dead.
In addition, the following clinical data were registered: DAS28 remission, LDA, health
assessment questionnaire score (HAQ), patient-scored visual analogue scales for pain (VAS-
pain), general health (VASglobal), physician’s global assessment of disease activity scored on
a visual analogue scale, 28 tender and swollen joint count, low disease activity, CDAI, SDAI
and C-reactive protein (CRP). DAS28, CDAI, and ACR20, ACR50, and ACR70 responses
compared to baseline were calculated at 6 months of follow-up. Patients were considered in
remission with a DAS28 score less than 2.6, and LDA was defined as DAS28 less than 3.2 at
follow-up.
Statistical analyses
In the analysis the first monotherapy treatment for each patient during the study period was
included (i.e. each patient was included once). Data were analyzed by Kruskal-Wallis test for
between-group comparisons regarding continuous variables, whereas a Chi-square test was
used for categorical variables. The Wilcoxon signed rank test was used to assess changes in
EQ-5D from baseline to the 6 month follow-up. For the discrete treatment outcomes, both
per-protocol and ITT-adjusted data (using the LUNDEX [18]) are given. The LUNDEX
adjustment is an ITT methodology developed for the observational setting to account both for
withdrawals from therapy and for missing response recordings at certain points of follow-up
[18]. Drug survival data were illustrated by Kaplan Meier plots and further statistically ana-
lysed with log-rank statistics for comparing different treatments. Level of significance was cho-
sen to be two-sided p<0.05.
Results
During the study period, a total of 554 patients were registered in SSATG as initiating
bDMARD monotherapy, as seen in Fig 1.
At baseline most of the patients were women (81%), with a mean age of 57 years. The aver-
age disease duration was more than 12 years, and on average the patients had previously been
treated with approximately four different csDMARDs. Fifty-five percent of the patients were
initiating their first bDMARD, 26% their second, and 19% their third or more. As presented in
Table 1, the average utility or preference-based measure of health (EQ-5D-3L) was 0.34. At the
time of inclusion, most patients had moderate to high disease activity, with mean scores for
DAS28 of 5.0, CDAI of 28.7, and SDAI of 31.1, and were substantially disabled, with an aver-
age HAQ score of 1.4 (Table 1).
Of the 554 patients in monotherapy, adalimumab (25.6%), etanercept (39.2%), rituximab
(11.2%), and infliximab (9.0%) were the 4 most prevalent bDMARDs administrated (Fig 1).
Utility during biological monotherapy in patients with rheumatoid arthritis
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Utility measure of health
At 6 months´ follow-up, the EQ-5D-3L in patients still on the biologic drug increased by mean
0.23 (SD 0.4) (p<0.001), indicating improvement of patients’ quality of life. The mean change
in EQ-5D-3L ranged from 0.11 (rituximab and infliximab) to 0.42 (tocilizumab) (Table 2).
Although the increases in EQ-5D-3L were numerically different, there was no statistically sig-
nificant difference across the various bDMARDs (Table 2).). There were no major differences
in sex (83% vs 78% females; p = 0.24), age (mean: 59.2 years vs 59.3 years; p = 0.37), disease
duration (mean: 15.6 years vs 14.4 years; p = 0.55), and DAS28 (mean: 5.1 vs 4.9; p = 0.16)
between patients reporting EQ-5D data and those with missing data.
Treatment responses
At 6 months´ follow-up, the crude DAS28 remission rates ranged from 0% (abatacept) to 27%
(adalimumab); LDA ranged from 27% (abatacept) to 67% (tocilizumab); ACR20 response rate
from 67% (abatacept and infliximab) to 90% (golimumab); ACR50 response rate from 22%
(tocilizumab) to 67% (certolizumab); and ACR70 response rate from 0% (abatacept and goli-
mumab) to 33% (certolizumab). Improvements of more than 0.3 in HAQ ranged from 18%
(rituximab) to 44% (certolizumab) (Table 2). Although the rates were numerically different,
these differences were not statistically significant (Table 2).
Fig 1. Study sample (flow diagram).
doi:10.1371/journal.pone.0169946.g001
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Overall, the crude mean change in DAS28 after 6 months was -1.4 and for CDAI -13.6
(Table 2). For DAS28 remission, the crude and LUNDEX corrected rates were 20% and 13%,
respectively, and for LDA the crude and LUNDEX corrected rates were 43% and 28%, respec-
tively. The crude and LUNDEX corrected response rates for ACR20/50/70 were 83%/55%/
21% and 54%/36%/14%, respectively (Table 2).
Drug survival, stratified by bDMARD
A total of 156 patients withdrew from treatment during the 6 months´ follow-up (Fig 1). The
overall drug survival rates were significantly different between the bDMARDs (p = 0.01).
Rituximab showed statistically significantly better drug survival than etanercept (p = 0.05),
whereas etanercept showed statistically significantly better drug survival rates compared to
both infliximab and adalimumab (Fig 2). The estimated overall drug survival was approxi-
mately 65% after 6 months, declining to approximately 55% after 2 years, with the exception of
abatacept, certolizumab, golimumab and tocilizumab having low number of patients and a
short follow-up time (Fig 2).
Fig 2. Drug survival, stratified by drug. The graph for the Kaplan-Meier estimated survival has been censored when the
number at risk was below 10. The number of patients on a drug at different time points is listed below the figure.
doi:10.1371/journal.pone.0169946.g002
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Drug survival in bDMARD switchers, anti-TNF vs. other modes of action
The estimated drug survival rates were statistically significantly different when comparing
anti-TNF switchers to other modes of action switchers (OMA switchers) (p = 0.02; Fig 3).
There was no statistically significant difference between anti-TNF naïve patients and OMA
switchers (p = 0.30) (Fig 3). The observed drug survival rates were similar irrespective of the
number of biologic treatments the patients had received previously (p = 0.41; Fig 4).
There were no statistically significant differences between anti-TNF naïve patients, anti-
TNF switchers, and OMA switchers regarding change in EQ-5D-3L, DAS28, HAQ, CDAI,
and the crude and LUNDEX corrected ACR response rates (Table 3) at 6 months follow-up.
Discussion
In the present study, based on the data from the south Swedish SSATG registry, we found that
the most common drugs used as biologic monotherapy were adalimumab, etanercept, and
rituximab. One of our main findings was that in RA patients receiving bDMARD monother-
apy, utility or preference-based health (EQ-5D-3L) on average nearly doubled after 6 months
of treatment with a bDMARD, indicating improvement of patients’ quality of health [19, 20].
Whether the absolute changes are clinically important remains to be validated in the RA popu-
lation. Although the changes were numerically different, no distinct pattern favored any
Fig 3. Drug survival, stratified by anti-TNF naive, anti-TNF switchers and other modes of action switchers (OMA
switchers) in biologic monotherapy. The graph for the Kaplan-Meier estimated survival has been censored when the
number at risk was below 10. The number of patients on a drug at different time points is listed below the figure.
doi:10.1371/journal.pone.0169946.g003
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particular bDMARD regarding change in health utility (EQ-5D-3L), remission and ACR
response criteria. Furthermore, the estimated survival rates were generally lower than seen in
combination therapy [21]. In addition, the survival rates seemed more favorable for rituximab
than for etanercept, whereas, etanercept showed significantly better drug survival rates com-
pared to both infliximab and adalimumab when given in monotherapy. On the other hand,
LUNDEX corrected treatment response rates and proportions achieving DAS28 defined
remission or low disease activity were not substantially different in patients treated with rituxi-
mab, etanercept and adalimumab.
The observed increase in health utility is in line with the utility gain found in an observa-
tional study by Gu¨lfe et al. [22] and in RCTs of biologic therapy in patients with RA receiving
concomitant csDMARDs [23, 24]. Comparison of change in utility score between bDMARD
monotherapy group and combination therapy group would be a clinically important issue to
investigate. However, with regard to background csDMARD usage this imposes an immense
confounding by indication, as these different patient groups are very heterogeneous in the
clinical setting [21]. Furthermore, this was not the scope of the current study, and must be
addressed in future studies.
EQ-5D was chosen as utility outcome because of its simplicity, patient acceptability and
well-established utilities. This adds important knowledge from a societal or payers perspective.
Fig 4. Drug survival, stratified by 1st, 2nd and 3rd line biologic monotherapy. The graph for the Kaplan-Meier estimated
survival has been censored when the number at risk was below 10. The number of patients on a drug at different time points is
listed below the figure.
doi:10.1371/journal.pone.0169946.g004
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This being said, EQ-5D is well suited for measuring health-related quality of life, including
dimensions such as pain, mobility, self-care and usual activities, all of which are important in
inflammatory joint diseases. However, EQ-5D entails several subjective judgments made by
the patients, wherefore it has major limitations for clinical monitoring and has to be comple-
mented with more objective measures before making decisions regarding the start or change
of bDMARD treatment.
Significantly better drug survival rates for etanercept compared to both infliximab and ada-
limumab have previously been shown in independent RA cohorts treated with csDMARDs
combination therapy [21, 25, 26], but it is to our knowledge the first time that this is demon-
strated in a unique monotherapy cohort. The finding that rituximab should be even less likely
to be discontinued is novel and could in part be due to methodologic issues. For example, the
pattern of administration with long inter-infusion times for rituximab probably contributes to
artificially improved drug survival in this analysis. As the study included more than four years
of follow-up, these patterns may also reflect true differences between bDMARDs in terms of
long term efficacy and safety. Of note, rituximab is often administered at a later state in the
treatment algorithm, wherefore limitation in the remaining treatment options might inflate
Table 3. Utility gain and effectiveness of anti-TNF naïve, anti-TNF switchers and other modes of
action (OMA) bDMARDs 6 months follow-up.
Anti-TNF naïve
(n = 269)
Anti-TNF switchers
(n = 160)
Other modes of
action (OMA)
(n = 83)
P-value
ΔEQ-5D
N 58 31 9
0.28 (0.3) 0.25 (0.4) 0.14 (0.3) 0.379
ΔDAS28
N 93 41 27
-1.6 (1.4) -1.6 (1.3) -1.7 (1,1) 0.897
ΔCDAI
N 94 45 27
-15.4 (13.2) -16.4 (11.7) -15.6 (11.7) 0.680
ΔHAQ
N 93 44 25
-0.3 (0.6) -0.3 (0.5) -0.1 (0.5) 0.100
ACR response
N 189 82 51
ACR20, no (%) 105 (56%) 37 (45%) 25 (49%) 0.261
LUNDEX corrected (%) 41% 29% 36%
N 189 82 51
ACR50, no (%) 61 (32%) 20 (24%) 11 (22%) 0.202
LUNDEX corrected (%) 13% 15% 16%
N 189 82 51
ACR70, no (%) 61 (32%) 20 (24%) 11 (22%) 0.202
LUNDEX corrected (%) 13% 15% 16%
N is the number of patients with complete recording of the particular outcome. ΔEQ5D, ΔDAS28, ΔCDAI,
and ΔHAQ are given as mean and standard deviation (SD). ACR responses are given as no. and percent
(%).
doi:10.1371/journal.pone.0169946.t003
Utility during biological monotherapy in patients with rheumatoid arthritis
PLOS ONE | DOI:10.1371/journal.pone.0169946 February 2, 2017 11 / 16
the drug survival rate in favor of rituximab. Future studies are needed to confirm our finding
and explore the underlying mechanisms.
Surprisingly, we found that when switching to OMA after anti-TNF failure the drug adher-
ence was as good as when treated with an anti-TNF as 1st course. However, switching to a 2nd
anti-TNF showed significantly inferior drug survival rates compared to bDMARDs with other
modes of action. Recently, an observational study comparing rituximab to anti-TNF in combi-
nation therapy also showed superiority when switching to OMA compared to another anti-
TNF [27]. Thus our results suggest that bDMARDs with other modes of action could be con-
sidered as the first choice for patients not tolerating csDMARDs and who have had an inade-
quate response to their first anti-TNF agent. It should be noted, that the favorable effect of
OMA is primarily driven by rituximab.
The clinical remission and response rates in the present study are comparable with results
from a study in the Danish DANBIO registry [8] showing somewhat lower overall remission
and response rates than in previously published studies in bDMARD therapy combined with
MTX [21, 25, 28–33].
The overall retention rate after 6 months was approximately 65%, declining to approxi-
mately 55% after 2 years, which is lower than the result observed in the DANBIO registry [8]
and generally lower than previously published studies on combination therapy [21, 26, 29–32].
The reason for the discrepancies in drug survival between SSATG and DANBIO might be due
to various reasons such as differences in the data capturing, regional prescription policies, and
the fact that the DANBIO report also included patients starting out in combination therapy,
but who withdrew from csDMARD during the course of the particular bDMARD.
In line with the monotherapy study from DANBIO [8], the survival rates found in the pres-
ent study were independent of previous treatments. Patients who were in their 2nd or 3rd line
of bDMARD as monotherapy adhered to the treatment as long as those who were on their first
biologic agent on monotherapy. This finding is in contrast with data from other registries on
RA patients in combination therapy [34, 35], showing that drug survival in switchers was
lower than in anti-TNF naïves [34, 36] and an increased risk of withdrawing from the second
treatment for the same reason as the first, regardless of whether it was due to inefficacy or
adverse events [35]. Other possibilities might be the pooling of anti-TNF bDMARDs and
bDMARDs with other modes of action in the present analysis which may have influenced the
drug survival in either direction for switchers, or that adherence to monotherapy depends
more on other factors (e.g., patients’ age and comorbidities).
Limitations and strengths
The non-randomized observational design of this study has limitations such as possible bias
regarding patient selection, assignment of treatment, baseline disparities between groups and
missing data. The patient background features and conditions were different, so one could
argue whether direct comparisons for outcomes among biologic agents is appropriate. Con-
founding by indication is an issue in the current study, being the inherent problem with all
observational studies. Thus, we have faded the role of direct comparison by grouping the dif-
ferent agents in larger groups (anti- TNF’s and OMA) in the main analysis performed. More-
over, regression-analysis was performed to compensate for confounding, however, residual
confounding always remains a problem in the observational study setting.
The Swedish national bDMARD registry [37] demonstrated that patients with many
comorbidities might have been channeled to non-TNF bDMARDs hampering the effective-
ness of these drugs. Moreover, TNF inhibition has previously been first line treatment in RA,
wherefore non-anti-TNF agents have been used more extensively as 2nd or 3rd line treatment,
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potentially deflating the response to these bDMARDs. This being said, summary disease char-
acteristics in this study were similar across different treatments, suggesting a limited potential
role of such confounding. Furthermore, decisions to start or stop therapy as well as concomi-
tant DMARDs were based solely on clinical practice and experience of treating physicians,
with national guidelines as a support.
Major strengths of the present study include access to prospectively recorded, routinely col-
lected registry data on biologic treatment. Observational data like ours are more generally
applicable as a reference for health economic modeling than randomized controlled trial data,
which are derived from highly selected patients. Observational studies remain important con-
tributors of information from daily clinical practice.
Conclusions
This observational study showed that utility (EQ-5D-3L) significantly increased after 6 months
of treatment with a bDMARD when applied in monotherapy, indicating improvement of
patients’ quality of life. Although there were numerical differences between bDMARDs in
terms of utility gain and clinical response, no distinct pattern favored any particular bDMARD
when used as monotherapy for RA. Survival rates were more favorable for rituximab than for
etanercept, whereas etanercept showed significantly better drug survival rates compared to
both infliximab and adalimumab. Furthermore, after anti-TNF failure, switching to a 2nd
anti-TNF drug showed significantly inferior drug survival rates compared starting one of the
bDMARDs with other modes of action.
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